Review: Kratom Alkaloids Mitragynine and Corynoxeine Relieve Pain Without Triggering Opioid Overdose Pathway

Why it matters

The opioid crisis kills tens of thousands each year, largely because opioids trigger the beta-arrestin-2 pathway that causes respiratory depression. If kratom-derived compounds achieve pain relief without this mechanism, they represent a fundamentally different and potentially safer class of analgesic.

The big picture

Opioid-related mortality reaches 80 deaths per 100,000 in some U.S. states, with an estimated annual economic burden of $1.5 trillion. Researchers urgently need safer alternatives. This systematic review from the Medical University of South Carolina finds that mitragynine and corynoxeine engage opioid receptors through a biased mechanism that avoids the beta-arrestin-2 activation responsible for respiratory depression — the same pharmacological property that makes experimental "G-protein biased" opioids so appealing to drug developers.

Key findings

• Mitragynine constitutes ~66% of kratom's total alkaloid content and acts as a partial mu-opioid receptor agonist with G-protein bias, avoiding beta-arrestin-2 activation
• Corynoxeine, a less-studied oxindole alkaloid, exhibits anti-inflammatory and neuroprotective effects alongside analgesic activity
• Neither alkaloid recruits beta-arrestin-2, the pathway linked to respiratory depression, severe constipation, and rapid opioid tolerance — the key drivers of opioid lethality
• Therapeutic potential was identified across five pain types: neuropathic, inflammatory, nociceptive, visceral, and central pain syndromes, including cancer pain
• Major barriers to clinical development include unregulated product quality, inconsistent potency from crude extracts, and limited long-term safety data

What they say

"Unlike traditional opioids, these compounds do not recruit beta-arrestin-2, avoiding key adverse effects such as respiratory depression, severe constipation, and rapid tolerance development. Their distinct pharmacological profiles make them innovative candidates for safer, non-lethal pain relief." — Alford et al., Pharmaceuticals, 2025

Bottom line

**A systematic review finds that kratom's mitragynine and corynoxeine relieve pain through opioid receptors while bypassing the beta-arrestin-2 pathway responsible for most opioid overdose deaths — positioning them as potential templates for a new generation of safer analgesics.**